Reviews/Epilepsy Management/Valproate superior in generalised epilepsy
Asm Efficacy · EP-ASM-02 · v2
The question is whether valproate controls generalised epilepsy better than lamotrigine. Across the studies that directly compare the two drugs, valproate comes out ahead on stopping seizures: two randomised trials and two hospital record reviews all point the same way. But the two large studies are based on looking back at patient records, where doctors tend to give lamotrigine to different kinds of patients, which can make valproate look better than it really is. The randomised trials that compared the drugs head to head were small, and one record review of women found the two drugs worked about equally well. The panel judged the direction of the finding solid and well repeated, but the strongest evidence was not a clean head-to-head test, so it stopped short of treating the claim as settled.
Within this corpus every direct valproate-versus-lamotrigine comparison favours valproate on seizure control: the randomised trial [7] reports 76.67% seizure-free on valproic acid versus 56.67% on lamotrigine, and the double-blind JME trial [5] found the lamotrigine group had significantly higher failure in controlling seizures (P=0.037). Two retrospective cohorts agree: [1] reports response rates of 71.1% for valproic acid versus 39.8% for lamotrigine, and [15] shows valproate seizure freedom of 47.2–60.0% against lamotrigine's best of 27.7%. The pragmatic RCT [3] corroborates valproate's high effectiveness in generalised epilepsy, but its generalised arm randomised valproate against levetiracetam, not lamotrigine. The one dissenting source [10] found 12-month seizure-freedom rates similar between valproate and alternatives including lamotrigine. The contested point: The division is between the consistent direction of effect and the strength of the evidence carrying it: the only large, highest-quality RCT [3] does not test lamotrigine, leaving the direct randomised support to two small trials [5][7], while the sizeable datasets [1][15] are observational and open to confounding by indication. One cohort [10] reporting similar seizure-freedom rates keeps the signal from being unanimous.
All 18 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Epilepsy Management, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The strongest randomised source in the corpus, SANAD II [3], tests valproate against levetiracetam in the generalised arm, not lamotrigine; the landmark direct VPA-vs-LTG RCT is absent, so the claim's direct RCT support rests on two small trials ([5] N=102, [7] N=60).
The large datasets [1][15] are retrospective and vulnerable to confounding by indication: lamotrigine is preferentially prescribed to women of childbearing age and milder phenotypes, which inflates valproate's apparent advantage.
Where it remains uncertain. The large datasets [1][15] are observational and vulnerable to confounding by indication, the in-corpus RCTs are small, and one cohort [10] found seizure-freedom rates similar between valproate and lamotrigine.
Aleatory
The direct randomised comparisons are small ([7] N=60, [5] N=102), so observed differences carry wide sampling variability.
Epistemic
The large cohorts [1][15] are retrospective; lamotrigine is preferentially prescribed to women of childbearing age and milder phenotypes, which can inflate valproate's apparent advantage.
The load-bearing papers from a corpus of 18, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Large IGE cohort: valproate response 71.1% vs lamotrigine 39.8%, favouring valproate.
“Lamotrigine, levetiracetam, and valproic acid showed differential response rates (39.8% vs 47.5% vs 71.1%) that were most pronounced in patients with juvenile myoclonic epilepsy.”
Panel auditInternal validity: medium · scope of inference: Adults with idiopathic generalised epilepsy, effectiveness as seizure response in routine care.Key limitations: retrospective, non-randomised · no p-value for VPA vs LTG contrast · higher VPA side-effects and lower retention noted
RCT confirming valproate's high effectiveness in generalised epilepsy, though the comparator is levetiracetam, not lamotrigine.
“In the per-protocol analysis of time to 12-month remission, valproate was superior to levetiracetam (hazard ratio 1.68, 95% confidence interval 1.30 to 2.15).”
Panel auditInternal validity: high · scope of inference: Generalised/unclassified epilepsy VPA vs LEV, and focal epilepsy LTG vs LEV/zonisamide.Key limitations: no VPA vs LTG arm · unblinded design
Double-blind RCT in JME: lamotrigine had significantly higher treatment failure than valproate.
“The rate of failure in controlling seizures and myoclonic jerks in lamotrigine group was meaningfully more than levetiracetam and sodium valproate (P=0.037).”
Panel auditInternal validity: medium · scope of inference: JME patients, monotherapy efficacy over 12 months.Key limitations: JME subtype only · p-value is across three groups · modest sample
3 of 18 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, multi-design signal favouring valproate clears Likely, but the thin and small direct RCT weight plus one contradicting cohort keep it below Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Adequately powered direct valproate-versus-lamotrigine RCT. The corpus's strongest RCT [3] tests levetiracetam, not lamotrigine; the direct randomised evidence rests on two small trials [5][7]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A pragmatic, adequately powered randomised non-inferiority or superiority trial of valproate versus lamotrigine monotherapy in generalised epilepsy with time-to-12-month-remission as the primary outcome.
Open question: Does valproate outperform lamotrigine for seizure control in a head-to-head randomised trial large enough to be decisive? Why it is still open: The one high-quality RCT in the corpus [3] substitutes levetiracetam for lamotrigine, and the direct RCTs [5][7] are small.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19